Zhejiang Cofine Biotech

Zhejiang Cofine Biotech is a clinical-stage biopharmaceutical company headquartered in Huzhou, China, specializing in the discovery and development of innovative small molecule drugs. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to develop next-generation therapies for oncology and autoimmune disorders. Its lead program, CFN-C042, is a potent BTK degrader designed to overcome resistance in B-cell malignancies and is currently in Phase 1 clinical trials. Cofine Biotech is supported by prominent venture capital firms including HighLight Capital and Sherpa Healthcare Partners. The company maintains research facilities dedicated to medicinal chemistry and translational medicine in both Huzhou and Shanghai.